TNGX - Tango Therapeutics, Inc.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.
Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,570 shares of the company's stock after purchasing an additional 125,930 shares during the
Bank of America Corp DE trimmed its stake in Tango Therapeutics, Inc. (NASDAQ: TNGX) by 31.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 327,144 shares of the company's stock after selling 150,918 shares during the quarter. Bank of
ADAR1 Capital Management LLC bought a new position in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 76,761 shares of the company's stock, valued at approximately $2,400,000. A number of other institutional investors have also made
Vopimetostat's combination with daraxonrasib has produced an unusually strong early pancreatic-cancer signal, but the evidence still comes from a very small, previously treated cohort. A planned front-line Phase 3 trial could substantially expand the opportunity, although its final design, timing, and regulatory path remain unsettled. Additional combination, lung-cancer, and CNS readouts should show whether TNGX is building a broader PRMT5 franchise or relying too heavily on one early dataset.
Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits.
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Shares of Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report) have received an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and thirteen have given a buy
The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tango Therapeutics, Inc. (NASDAQ: TNGX - Get Free Report)'s share price shot up 6.1% on Friday. The stock traded as high as $29.25 and last traded at $29.3360. 316,615 shares changed hands during trading, a decline of 91% from the average daily volume of 3,701,445 shares. The stock had previously closed at $27.64. Analyst Upgrades
Tango Therapeutics' strong 2026 rally reflects promising clinical progress, but its premium valuation puts upcoming study results at the center of the next move.
TNGX is advancing precision oncology with MTAP-targeted therapies and 2026 data readouts that could test its clinical and commercial potential.
Tango Therapeutics enters a pivotal phase as vopimetostat drives its investment case, with 2026 clinical updates set to test its focused oncology pipeline.
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings more than three decades of leadership experience across the biopharmaceutical industry, including deep expertise in oncology commercialization, corporate strategy, company building and board governance. His appointment comes as Tango advances vopimetostat, its investigational PRMT5 inhibitor with first- and best-in-class potential, toward potential late-stage development for patients with pancreatic cancer.
BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the pricing of an underwritten offering of 18,166,667 shares of its common stock and pre-funded warrants to purchase up to 1,833,395 shares of its common stock (the “Offering”). The offering price of each share of common stock is $30.00. The offering price of each pre-funded warrant is $29.999, which represents the per share offering price for the common stock less the $0.001 per share exercise price for such pre-funded warrant. The gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering-related expenses, are expected to be approximately $600 million. All of the shares and pre-funded warrants in the Offering are to be sold by Tango. The Offering is expected to close on or about June 11, 2026, subject to customary closing conditions. In addition, Tango has granted the underwriters a 30-day option to purchase up to an additional 3,000,009 shares of common stock at the public offering price, less the underwriting discount.
Tango Therapeutics rises 53% after early pancreatic cancer study data show strong response rates for vopimetostat combinations and support late-stage plans.
Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript
BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, announced today the launch of an underwritten public offering (the “Offering”) of $500 million of its common stock. All shares of common stock to be sold in the Offering will be offered by Tango. Tango also intends to grant the underwriters a 30-day option to purchase up to an additional $75,000,000 of shares of its common stock offered in the Offering under the same terms and conditions. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or the actual size or terms of the Offering.
Shares of Tango Therapeutics (TNGX) surged more than 51% on Monday after the clinical-stage biotechnology company reported encouraging early-stage trial results for its experimental cancer treatment, vopimetostat. The drug was tested in combination with Revolution Medicines' daraxonrasib.